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Objective:This study documents mid-term outcomes of a series of endovascular popliteal aneurysm repairs compared with
concurrent results of open surgical repair.
Methods: A retrospective chart review was done of all popliteal artery aneurysm repairs since January 1, 2000. Patency was
defined as continued presence of palpable pulses or maintenance of postoperative ankle-brachial index 0.15. Statistical
methods included 2, t test, Fisher’s exact test, and Kaplan-Meier plots with log-rank comparison.
Results: A total of 56 popliteal artery aneurysm repairs were performed. All endovascular popliteal aneurysm repairs
(EVPAR, n  15) were performed using Viabahn endoprostheses. Patients with open repair (OR, n  41) underwent
surgical bypass and aneurysm exclusion with great saphenous vein (n  26), short saphenous vein (n  3), or
polytetrafluoroethylene (n  12), through either a medial (n  28) or posterior (n  13) approach. All urgent cases
received open repair. Technical success was 100% in both groups. Mean follow-up was 16.5 3 months (range, 0.5 to 56
months). Aneurysm size, location, and outflow were similar between groups. Primary patency, secondary patency, and
survival did not differ between groups. Endoleaks were observed in three (20%) of 15 endovascular cases, and type I and
III endoleaks were treated with additional endografts.
Conclusion: To our knowledge, this represents the largest United States series of EVPAR to date. Early mid-term results
of elective endovascular repair of popliteal artery aneurysms are encouraging. Further studies are warranted to define
optimal indications for EVPAR and to generate long-term outcomes for this technique. (J Vasc Surg 2007;45:505-10.)Popliteal artery aneurysm (PAA) is the most commonly
encountered peripheral arterial aneurysm. Owing to high
rates of thromboembolic complications, PAA confers signif-
icant risk of limb loss, and surgical exclusion has been advo-
cated for aneurysms displaying mural thrombus or 2 cm in
diameter. Marin et al1 first described the use of a covered stent
as a means of PAA repair in 1994. Although early reports
detailed the technical feasibility of endovascular popliteal an-
eurysm repair (EVPAR), outcomes with first-generation de-
vices were poor.2 The subsequent introduction of expanded
polytetrafluoroethylene (ePTFE)-lined nitinol stents, such as
the Viabahn endoprosthesis (W. L. Gore & Assoc, Inc, Flag-
staff, Ariz), has renewed interest in the potential application of
these devices to EVPAR.
This report reviews our 6-year experience with both
EVPAR and open repair (OR) of PAAs at Washington
University. Indications, technique, and early mid-term re-
sults for our EVPAR experience are compared with con-
temporaneous OR outcomes.
METHODS
A retrospective review was performed of all patients
who underwent PAA repair at Washington University from
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tocol was approved by the institutional Human Studies
Committee. Hospital records, clinic notes, and vascular
laboratory reports were used to compile a database of all
PAA repairs. Procedures were grouped by method of repair
(EVPAR vs OR). The two groups were then compared,
with graft patency as the primary end point. Secondary end
points included complication rates, frequency of endoleak,
and overall survival.
Indications, complications, endoleak characterization,
patency rates, and survival are reported in accordance with
recommended standards.3,4 Symptomatic patients in-
cluded those experiencing claudication, rest pain, em-
bolic stigmata, or venous hypertension attributed to the
PAA. Urgent procedures were those undertaken after the
minimum necessary preoperative studies; in general, urgent
operation was dictated by a perceived limb threat. Outflow
was characterized as the number of tibial vessels intact from
origin to ankle. Patency was defined as continued presence
of palpable pulses or maintenance of a postoperative ankle-
brachial index (ABI) with a change of 0.15.
Statistical analysis. Statistical analysis was performed
using SPSS software (SPSS, Inc, Chicago, Ill) for Windows
(Microsoft Corp, Redmond, Wash). Patient characteristics,
indications, and complications were compared using Pear-
son 2 analysis.Mann-Whitney tests were used for nonpara-
metric comparison of means. Patency and survival rates
were compared using Kaplan-Meier plots and log-rank
analysis. Statistical significance was accepted at P  .05.
Endovascular popliteal aneurysm repair technique.
EVPAR was accomplished using Viabahn endoprostheses
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able in diameters of 5 to 13 mm, and lengths of 2.5 to 15
cm. The introducer sheath size required for graft placement
ranges from 8F to 12F. Computed tomography (CT) an-
giography was the favored preoperative imaging modality.
Although rigid guidelines for EVPAR technique were
not established at the outset of our experience, proximal
and distal landing zones of nonaneurysmal artery of2 cm
length were sought, with the distal terminus of the en-
dograft(s) not extending beyond the popliteal artery. En-
dografts were oversized 10% to 15% relative to the landing
zones. When sequential endografts were required to
achieve aneurysm exclusion, 2 to 3 cm of overlap between
endografts was generally used. Overlapping endografts dif-
fered by no more than 2 mm in diameter, because greater
differences in diameter may lead to longitudinal pleating of
the larger graft, with loss of seal.
Arterial access was accomplished by a mini-cutdown to
the common femoral or proximal superficial femoral artery,
percutaneous antegrade approach, or percutaneous retro-
grade crossover approach. Because the sheath sizes re-
quired for repair proscribe the use of most closure devices,
the small cutdown permits placement of a transverse mat-
tress suture at the intended antegrade arterial puncture site.
Intraoperative imaging of landing zones with a 0.018-inch
guidewire-compatible intravascular ultrasound probe (Vol-
cano, Rancho Cordova, Calif) was frequently used to com-
plement intraoperative angiography. Figs 1, 2, 3, and 4
show intraoperative angiograms from a representative
EVPAR procedure.
RESULTS
A total of 43 patients underwent PAA repair in 56
Fig 1. Initial angiogram shows the left popliteal artery aneurysm.limbs. Of these, 30 patients underwentOR in 41 limbs, and13 patients underwent EVPAR in 15 limbs. Patient char-
acteristics are summarized in Table I. The patients treated
for PAA were primarily men in the seventh and eighth
decades of life. Patient groups differed only in respect to
age. The EVPAR group was a mean 7 years older than the
OR group (75  1.6 vs 68  2.4, P  .05). Rates of
comorbidities were high and similar between groups
(Table I). A contralateral PAA was present in 70% of
patients.
A significantly higher percentage of OR cases (54%)
Fig 2. Under roadmap guidance, the Viabahn endoprosthesis is
positioned.
Fig 3. The endograft is deployed.were performed for symptomatic patients vs EVPAR (13%;
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EVPAR, P  NS). Anatomic variables related to aneurysm
size and tibial outflow vessels (Table II) did not differ
significantly between groups. Of note, approximately one
third of patients in each group had single vessel runoff at
the time of surgery.
All EVPAR cases were performed using the Viabahn
endoprosthesis. Open cases (n  41) underwent surgical
bypass and aneurysm exclusion with great saphenous vein
(n 26), short saphenous vein (n 3), or PTFE (n 12)
through either a medial (n  28) or posterior (n  13)
approach. Outflow thrombectomy or thrombolysis was
performed in eight (15%) cases and did not differ between
Fig 4. Completion angiogram demonstrates exclusion of the
popliteal artery aneurysm.
Table I. Patient demographics and risk factors
EVPAR (%)* OR (%)*
(n  15) (n  41)
Age, years 75  1.6 68  2.4†
Male 93 93
Hypertension 67 73
Coronary disease 60 54




History of AAA 53 37
Bilateral PAA 67 79
EVPAR, Endovascular popliteal aneurysm repair; OR, open repair; MI,
myocardial infarction; COPD, chronic obstruction pulmonary disease;
AAA, abdominal aortic aneurysm; PAA, popliteal aortic aneurysm.
*Data are presented % for categoric variables and mean  SEM for contin-
uous variables.
†P  .05.groups (7% EVPAR vs 17% OR, P  NS). In two EVPARprocedures (13%), dilation of stenosis adjacent to the PAA
was performed before endograft delivery. The dilated area
was subsequently covered by the deployed endograft.
Technical success was 100% in both groups.
Although no EVPAR patients were anticoagulated,
22% of the OR group was discharged on warfarin therapy
(P  .05). Indications for warfarin therapy included long-
term treatment of intracranial atherosclerosis or atrial fibril-
lation (44%) and a new diagnosis of hypercoagulable state
(22%). Use of warfarin therapy did not appear to influence
patency rates. Nearly all EVPAR patients (87%) were
treated with clopidogrel, compared with 11% of the OR
group (P  .05). Mean length of stay was significantly
shorter in the EVPAR group (0.9  0.2 days vs 4.9  .5
days). Comparative treatment data are summarized in Ta-
ble III, and additional data on EVPAR are provided in
Table IV.
Major complications occurred in 7% of patients in both
groups. One EVPAR patient experienced femoral puncture
site bleeding that required suture repair; this patient had
received percutaneous antegrade arterial access with 9F
sheath placement. Wound abscesses developed in three OR
patients that required intervention, and one of these infec-
tions resulted in sepsis and death.
Mean follow-up was 14  3 months for EVPAR and
17  3 months for OR (total mean, 16.5  3 months;
Table II. Surgical indications and anatomy
EVPAR (n  15) OR (n  41)
Median diameter (cm) 2.5 2.6
Symptomatic (%) 13 54*





EVPAR, Endovascular popliteal aneurysm repair; OR, open repair.
*P  .05.





Outflow thrombolysis 1 (7) 7 (17)
Proximal terminus
CFA 0 8 (20)
SFA 14 (93) 12 (29)
Popliteal 1 (7) 21 (51)
Distal terminus
Popliteal 15 (100) 36 (88)
Tibial 0 5 (12)
LOS (mean, days) 1 5*
Post-op warfarin 0% 22%*
Post-op clopidogrel 87% 11%*
EVPAR, Endovascular popliteal aneurysm repair; OR, open repair; CFA,
common femoral artery; SFA, superficial femoral artery; LOS, length of stay.
*P  .05.range, 0.5 to 56 months). At 24 months, primary patency
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(100% vs 92%  5%, P  NS), and survival (90%  9% vs
90% 6%, PNS) did not differ between the EVPAR and
OR groups, respectively (Figs 5, 6, and 7). Comparison of
only electively performed repairs (Fig 8) also demonstrated
no difference in secondary patency at 24 months between
OR (92  8%) and EVAR (100%).
Endoleaks have been detected in three (20%) of 15
EVPAR patients. A combined type I and type III endoleak
owing to endograft migration was found in one patient.
This was resolved by deployment of additional endografts.
Type II endoleaks were found in two additional patients
and were followed up conservatively, with shrinkage of one
PAA and no change in the other.
DISCUSSION
Acute ischemia is the first presenting symptom in 20%
to 50% of patients with PAA. Continued observation of
asymptomatic PAA is associated with complication rates of
15% to 25% at 1 year and 60% to 75% at 5 years.5,6 To
prevent the limb loss and morbidity engendered by throm-
boembolic complications, early repair of asymptomatic an-
Fig 5. Kaplan-Meier analysis of primary patency of open repair
(OR) compared with endovascular popliteal aneurysm repair
(EVPAR). Broken lines indicate SEM 10%.
Table IV. Intraoperative endovascular popliteal
aneurysm repair variables
Variable N (%)*
Sheath size (median, range) 10F (8F-12F)
Access
Cutdown - antegrade 11 (73)
Percutaneous - antegrade 3 (20)
Percutaneous retrograde 1 (7)




Endograft size (mm) 8 (6-11)
IVUS imaging 6 (40)
IVUS, Intravascular ultrasound.
*Data are presented as n (%) for categoric variables and median (range) for
continuous variables.eurysms exceeding2 cm or containing mural thrombus isrecommended.7 This has traditionally been accomplished
with elective open surgical repair of PAA and has yielded
5-year secondary patency rates of 60% to 80%.8-13 Factors
Fig 6. Kaplan-Meier analysis of secondary patency of open
repair (OR) compared with endovascular popliteal aneurysm
repair (EVPAR).
Fig 7. Kaplan-Meier analysis of patient survival after undergoing
open repair (OR) compared with endovascular popliteal aneurysm
repair (EVPAR).
Fig 8. Secondary patency of endovascular repairs (EVPAR) com-
pared with only the elective open repairs (OR) showing no signif-
icant difference between groups.affecting patency and limb salvage include the number of
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Although open surgical repair effectively mitigates the
risk of thromboembolic complication, investigators have
sought to adapt endovascular technology to PAA repair.
Howell et al14 repaired 13 aneurysms using the Wallgraft
endoprosthesis (Boston Scientific, Natick, Mass), but
thrombosis was detected in 31% at 12 months’ follow-up.14
More recently, Tielliu et al15 reported a series of 57 cases
in which EVPAR was performed using Viabahn stent grafts.
Technical success was 100%. Primary and secondary patency
rates at 2 years were 77% and 87%. Acute ischemia was the
indication for PAA repair in five (8.8%) of 57, and only one
third of patients received postprocedural antiplatelet or anti-
coagulation therapy. The only variable found to be associated
with success was treatment with clopidogrel.
Antonello et al16 published a prospective randomized
trial comparing 15 OR and 15 EVPAR in patients with
PAA 2 cm, adequate proximal and distal landing zones,
and acceptable outflow.16 These patients were significantly
younger than in the current series, with a mean age of 63,
and all were suitable candidates for open repair. With
primary and secondary patency rates of 87% and 100% at 24
months, the results in this randomized group were remark-
ably similar to those in the current report.17
CONCLUSION
This retrospective review demonstrates encouraging
mid-term results of EVPAR in a small group of selected
patients. Reasonable patency rates were achieved, and no
instances of limb loss occurred. However, several weak-
nesses of the study necessitate caution at this juncture:
1. Study design and duration. As noted, the relatively low
numbers of patients and early mid-term follow-up do
not permit us to forecast long-term outcomes.
2. Absence of standardized inclusion and exclusion criteria.
The recommendation for EVPAR was ultimately made
at the surgeon’s discretion, although patient variables
(other than advanced age) favoring the use of EVPAR
included absent or inadequate saphenous vein conduit
(33%), simultaneous or recent other major surgery
(27%), and symptomatic contralateral lower extremity
occlusive disease (20%). All urgent cases andmost symp-
tomatic cases underwent open repair, likely reflecting
reluctance on the part of our surgeons to attempt this
new technique on the subset of patients at greatest risk
for limb loss. Therefore, although the patency outcomes
in Figs 5 to 8 are of interest, the heterogeneous nature of
patient groups studied mandates caution in their inter-
pretation.
Anatomic contraindications to EVPAR have not
been well defined, but landing zones diameters 12
mm and 4 mm would not be expected to offer ade-
quate seal with the available Viabahn endoprostheses.
Likewise, wide variation in the diameters of the proximal
and distal landing zones may preclude an appropriate
telescoping of grafts, particularly when the length ofaneurysm to be covered is short. Finally, within our
group, predicted terminus of repair within a tibial artery,
or covering the orifice of a patent tibial artery, is felt to
negate consideration for EVPAR.
3. Variables related to procedure and endograft. Variables
such as the length of the landing zone and overlap
between components were not standardized; indeed,
the appropriate lengths in each instance have yet to be
rigorously established. Such variables can affect en-
dograft performance: in the solitary EVPAR that devel-
oped type I and III endoleaks, a review of radiographic
images suggests that the initial distal landing zone and
overlap between endograft components may have been
as little as 1 cm in length. Long-term durability of the
Viabahn endograft in popliteal aneurysms, including the
rate and clinical significance of nitinol component frac-
tures, remains unknown.
The current series should not be misrepresented as an
endorsement of the unrestricted use of EVPAR. Further
studies will be needed to define the optimal role and
candidates for this technique.
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